Budiodarone free base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 3330957

CAS#: 335148-45-3 (free base)

Description: Budiodarone, also known as ATI-2042, is an antiarrhythmic agent and chemical analog of amiodarone. Budiodarone has a half life of 7 h. It is electrophysiologically similar to amiodarone, but may not have metabolic and interaction side effects. ATI-2042 effectively reduced AFB over all doses studied by reducing mean episode duration. Budiodarone holds much promise as an antiarrhythmic drug to prevent fibrillation. As a drug that spans over many of antiarrhythmic drug classes, the electrophysiological activity of budiodarone includes.

Chemical Structure

Budiodarone free base
CAS# 335148-45-3 (free base)

Theoretical Analysis

MedKoo Cat#: 3330957
Name: Budiodarone free base
CAS#: 335148-45-3 (free base)
Chemical Formula: C27H31I2NO5
Exact Mass: 703.0292
Molecular Weight: 703.3559
Elemental Analysis: C, 46.11; H, 4.44; I, 36.09; N, 1.99; O, 11.37

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 478941-80-9 (HCl)   478941-93-4 (tartrate)   335148-45-3 (free base)   478941-90-1 (maleate)   478941-86-5 (fumarate)   478941-98-9 (citrate)    

Synonym: Budiodarone free base; (S)-ATI 2042; ATI-2042; ATI2042; ATI 2042; Budiodarone;

IUPAC/Chemical Name: (S)-sec-butyl 2-(3-(4-(2-(diethylamino)ethoxy)-3,5-diiodobenzoyl)benzofuran-2-yl)acetate


InChi Code: InChI=1S/C27H31I2NO5/c1-5-17(4)34-24(31)16-23-25(19-10-8-9-11-22(19)35-23)26(32)18-14-20(28)27(21(29)15-18)33-13-12-30(6-2)7-3/h8-11,14-15,17H,5-7,12-13,16H2,1-4H3/t17-/m0/s1


Appearance: To be determined

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 703.3559 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Bunch TJ, Anderson JL. Adjuvant antiarrhythmic therapy in patients with implantable cardioverter defibrillators. Am J Cardiovasc Drugs. 2014 Apr;14(2):89-100. doi: 10.1007/s40256-013-0056-x. PMID: 24288157.

2: Whitehead DM, Hartmann S, Ilyas T, Taylor KR, Kohler AD, Ellames GJ. A convenient method to produce [(14) C]carbon monoxide and its application to the radiosynthesis of [carboxyl-(14) C]celivarone, [carboxyl-(14) C]SSR149744. J Labelled Comp Radiopharm. 2013 Feb;56(2):36-41. doi: 10.1002/jlcr.3009. Epub 2013 Jan 22. PMID: 24285280.

3: Khitri AR, Aliot EM, Capucci A, Connolly SJ, Crijns H, Hohnloser SH, Kulakowski P, Roy D, Radzik D, Kowey PR. Celivarone for maintenance of sinus rhythm and conversion of atrial fibrillation/flutter. J Cardiovasc Electrophysiol. 2012 May;23(5):462-72. doi: 10.1111/j.1540-8167.2011.02234.x. Epub 2011 Dec 15. PMID: 22171925.

4: Kowey PR, Crijns HJ, Aliot EM, Capucci A, Kulakowski P, Radzik D, Roy D, Connolly SJ, Hohnloser SH; ALPHEE Study Investigators. Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter- defibrillator interventions or death: the ALPHEE study. Circulation. 2011 Dec 13;124(24):2649-60. doi: 10.1161/CIRCULATIONAHA.111.072561. Epub 2011 Nov 14. PMID: 22082672.

5: Gojkovic O, Aliot EM, Capucci A, Connolly SJ, Crijns H, Hohnloser SH, Kulakowski P, Roy D, Radzik D, Singh BN, Kowey PR. Celivarone in patients with an implantable cardioverter-defibrillator: adjunctive therapy for the reduction of ventricular arrhythmia-triggered implantable cardioverter-defibrillator interventions. Heart Rhythm. 2012 Feb;9(2):217-224.e2. doi: 10.1016/j.hrthm.2011.09.073. Epub 2011 Oct 4. PMID: 21978965.

6: Gramley F, Himmrich E, Mollnau H, Theis C, Hammwohner M, Goette A. Recent advances in the pharmacological treatment of cardiac arrythmias. Drugs Today (Barc). 2009 Nov;45(11):807-24. doi: 10.13581/dot.2009.45.11.1412574. Erratum in: Drugs Today (Barc). 2010 Jan;46(1):69. PMID: 20126673.

7: Mason PK, DiMarco JP. New pharmacological agents for arrhythmias. Circ Arrhythm Electrophysiol. 2009 Oct;2(5):588-97. doi: 10.1161/CIRCEP.109.884429. PMID: 19843928.

8: Verma A. Alternatives to amiodarone: search for the Holy Grail. Europace. 2009 Apr;11(4):402-4. doi: 10.1093/europace/eup042. Epub 2009 Feb 17. PMID: 19223364.

9: Arya A, Silberbauer J, Teichman SL, Milner P, Sulke N, Camm AJ. A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology. Europace. 2009 Apr;11(4):458-64. doi: 10.1093/europace/eun384. Epub 2009 Jan 26. PMID: 19174378; PMCID: PMC2659603.

10: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 May;30(4):313-31. PMID: 18773127.

11: Han TS, Williams GR, Vanderpump MP. Benzofuran derivatives and the thyroid. Clin Endocrinol (Oxf). 2009 Jan;70(1):2-13. doi: 10.1111/j.1365-2265.2008.03350.x. Epub 2008 Aug 22. PMID: 18727707.

12: Naccarelli GV, Wolbrette DL, Samii S, Banchs JE, Penny-Peterson E, Gonzalez MD. New antiarrhythmic treatment of atrial fibrillation. Expert Rev Cardiovasc Ther. 2007 Jul;5(4):707-14. doi: 10.1586/14779072.5.4.707. PMID: 17605649.

13: Gautier P, Serre M, Cosnier-Pucheu S, Djandjighian L, Roccon A, Herbert JM, Nisato D. In vivo and in vitro antiarrhythmic effects of SSR149744C in animal models of atrial fibrillation and ventricular arrhythmias. J Cardiovasc Pharmacol. 2005 Feb;45(2):125-35. doi: 10.1097/01.fjc.0000151899.03379.76. PMID: 15654261.

14: Gautier P, Guillemare E, Djandjighian L, Marion A, Planchenault J, Bernhart C, Herbert JM, Nisato D. In vivo and in vitro characterization of the novel antiarrhythmic agent SSR149744C: electrophysiological, anti-adrenergic, and anti-angiotensin II effects. J Cardiovasc Pharmacol. 2004 Aug;44(2):244-57. doi: 10.1097/00005344-200408000-00015. PMID: 15243307.

15: Morey TE, Seubert CN, Raatikainen MJ, Martynyuk AE, Druzgala P, Milner P, Gonzalez MD, Dennis DM. Structure-activity relationships and electrophysiological effects of short-acting amiodarone homologs in guinea pig isolated heart. J Pharmacol Exp Ther. 2001 Apr;297(1):260-6. PMID: 11259553.